

Financial news for ZFGN dated on 2020-06-02: Larimar Therapeutics (Formerly Zafgen) 8-K Shows Securities Purchase Deal For Private Placement Of 6.105M Shares, Pre-Funded Warrants For ~628K Shares At \$11.8/Share, Warrant

Financial news for ZFGN dated on 2020-05-29: The Daily Biotech Pulse: ASCO Presentations Begin, Altimune Pops On Insider Buying, Immuteq Gets R&D Grant

Financial news for ZFGN dated on 2020-05-28: Zafgen Shares Volatile Over Last Few Mins, Make Parabolic Move, Following Circulation Of Report Deal With Larimar Therapeutics Was Approved

Financial news for ZFGN dated on 2020-05-07: 20 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for ZFGN dated on 2020-03-20: The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company

Financial news for ZFGN dated on 2020-03-05: Zafgen Q4 EPS \$(0.19) Up From \$(0.39) YoY

Financial news for ZFGN dated on 2020-02-12: Renaissance Technologies Reports 6.38% Passive Stake In Zafgen

Financial news for ZFGN dated on 2020-02-11: Sphera Funds Management Reports 7.59% Passive Stake In Zafgen

Financial news for ZFGN dated on 2020-01-22: 98 Biotechnology Stocks Moving In Wednesday's Session

Financial news for ZFGN dated on 2020-01-22: 116 Healthcare Stocks Moving In Wednesday's Session

Financial news for ZFGN dated on 2019-12-30: Chondrial Therapeutics Reports 14.4% Active Stake In Zafgen

Financial news for ZFGN dated on 2019-12-19: 36 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for ZFGN dated on 2019-12-19: The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic

Financial news for ZFGN dated on 2019-12-18: Stocks That Hit 52-Week Lows On Wednesday

Financial news for ZFGN dated on 2019-12-18: 30 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for ZFGN dated on 2019-12-18: Zafgen and Chondrial Therapeutics Announce Definitive Merger Agreement; Zafgen Shareholders to Own 40% of Combined Co

Financial news for ZFGN dated on 2019-12-18: Zafgen And Chondrial Announce Merger Agreement Under Which Chondrial Will Become A Wholly-Owned Subsidiary Of Zafgen

Financial news for ZFGN dated on 2019-11-06: Zafgen Q3 EPS \$(0.35) Misses \$(0.27) Estimate

Financial news for ZFGN dated on 2019-10-15: Zafgen 13G Filing From EcoR1 Capital Shows 7% Stake

Financial news for ZFGN dated on 2019-10-11: Zafgen Shares Resume Trade, Down 2.09%

Financial news for ZFGN dated on 2019-09-12: Zafgen Commences Reduction In Workforce; Co. To Cut Employees By ~48%

Financial news for ZFGN dated on 2019-09-09: 27 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for ZFGN dated on 2019-09-06: Benzinga's Top Upgrades, Downgrades For September 6, 2019

Financial news for ZFGN dated on 2019-09-06: 16 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for ZFGN dated on 2019-09-06: The Daily Biotech Pulse: European Nod For Roche, Takeda Recall, Neon Exults On Journal Publication

Financial news for ZFGN dated on 2019-09-06: Wedbush Downgrades Zafgen to Neutral, Lowers Price Target to \$0.78

Financial news for ZFGN dated on 2019-09-05: Zafgen To Explore Strategic Options, With No Near-Term Resolution For Diabetes Drug

Financial news for ZFGN dated on 2019-09-05: JMP Securities Downgrades Zafgen to Market Perform

Financial news for ZFGN dated on 2019-09-05: Zafgen Shares Resume Trade, Up 8%

Financial news for ZFGN dated on 2019-09-05: Zafgen Shares To Resume Trade At 7:30 a.m. EDT

Financial news for ZFGN dated on 2019-09-05: Zafgen To Explore Strategic Alternatives

Financial news for ZFGN dated on 2019-09-05: Zafgen Shares Halted News Pending

Financial news for ZFGN dated on 2019-08-28: The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved

Financial news for ZFGN dated on 2019-08-27: The Daily Biotech Pulse: Nuvectra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO

Financial news for ZFGN dated on 2019-08-08: Zafgen Q2 EPS \$(0.32) Beats \$(0.36) Estimate

Financial news for ZFGN dated on 2019-08-06: Stocks That Broke Yearly Lows Tuesday Morning

Financial news for ZFGN dated on 2019-08-02: 40 Healthcare Stocks Moving In Thursday's After-Market Session

Financial news for ZFGN dated on 2019-07-30: New 52-Week Lows for Tuesday Morning

Financial news for ZFGN dated on 2019-07-30: The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings

Financial news for ZFGN dated on 2019-07-25: The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug

Financial news for ZFGN dated on 2019-07-25: 35 Healthcare Stocks Moving In Wednesday's After-Market Session

Financial news for ZFGN dated on 2019-07-24: Zafgen Reports Deal FDA On New Nonclinical Study Design For ZGN-1061; Topline Data From In Vivo Study Expected By End Of 2019

Financial news for ZFGN dated on 2019-07-24: The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index

Financial news for ZFGN dated on 2019-07-23: List of Companies Reaching Yearly Lows Tuesday

Financial news for ZFGN dated on 2019-07-23: The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation

Financial news for ZFGN dated on 2019-06-28: The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO

Financial news for ZFGN dated on 2019-06-10: Zafgen Highlights Full Results Of Phase 2 Trial For ZGN-1061 At American Diabetes Association's 79th Scientific Sessions

Financial news for ZFGN dated on 2019-06-07: The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix

Financial news for ZFGN dated on 2019-06-06: The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering

Financial news for ZFGN dated on 2019-05-31: The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering

Financial news for ZFGN dated on 2019-05-31: 56 Biggest Movers From Yesterday

Financial news for ZFGN dated on 2019-05-30: Mid-Afternoon Market Update: BOS Better Online Solutions Falls After Q1 Results; Organovo Holdings Shares Rise

Financial news for ZFGN dated on 2019-05-30: 44 Stocks Moving In Thursday's Mid-Day Session

Financial news for ZFGN dated on 2019-05-30: Mid-Day Market Update: Crude Oil Down 1.7%; Titan Machinery Shares Surge Following Upbeat Q1 Results

Financial news for ZFGN dated on 2019-05-30: Micro-Cap Biotech Zafgen Plunges To Record Low: What You Need To Know

Financial news for ZFGN dated on 2019-05-30: Mid-Morning Market Update: Markets Open Higher; Dollar General Tops Q1 Expectations

Financial news for ZFGN dated on 2019-05-30: Zafgen shares are trading lower after the company announced it received FDA Type A meeting minutes related to the previously announced clinical Hold on its ZGN-1061.

Financial news for ZFGN dated on 2019-05-30: Zafgen Announces Receipt Of Type A Meeting Minutes From FDA Regarding Clinical Hold For ZGN-1061; Co. Is Also Exploring A Second IND For ZGN-1061 In A Population With A Higher Inmet Medical Need

Financial news for ZFGN dated on 2019-05-30: 64 Biggest Movers From Yesterday

Financial news for ZFGN dated on 2019-05-09: Zafgen Q1 EPS \$(0.35) Beats \$(0.42) Estimate

Financial news for ZFGN dated on 2019-04-26: Roth Capital Initiates Coverage On Zafgen, Inc. - Common Stock with Buy Rating

Financial news for ZFGN dated on 2019-04-25: The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings

Financial news for ZFGN dated on 2019-04-24: The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediCinova

Financial news for ZFGN dated on 2019-04-23: The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale

Financial news for ZFGN dated on 2019-03-26: The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

Financial news for ZFGN dated on 2019-03-13: The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie

Financial news for ZFGN dated on 2019-03-13: 56 Biggest Movers From Yesterday

Financial news for ZFGN dated on 2019-03-12: Mid-Afternoon Market Update: Momo Rises On Upbeat Q4 Results; Valhi Shares Slide

Financial news for ZFGN dated on 2019-03-12: 42 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ZFGN dated on 2019-03-12: Mid-Day Market Update: Stitch Fix Jumps Following Strong Q2 Results; Zafgen Shares Plummet

Financial news for ZFGN dated on 2019-03-12: Mid-Morning Market Update: Markets Mixed; Dicks Sporting Goods Profit Tops Views

Financial news for ZFGN dated on 2019-03-12: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ZFGN dated on 2019-03-12: The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug

Financial news for ZFGN dated on 2019-03-12: A Peek Into The Markets: US Stock Futures Mostly Higher Ahead Of Consumer Price Index

Financial news for ZFGN dated on 2019-03-12: 7 Stocks To Watch For March 12, 2019

Financial news for ZFGN dated on 2019-03-11: Zafgen shares are trading lower after the company announced it suspended its plans to file an IND application for ZGN-1258, based on a recent unexpected nonclinical finding in long-term toxicology studies.

Financial news for ZFGN dated on 2019-03-11: 5 Stocks Moving In Monday's After-Hours Session

Financial news for ZFGN dated on 2019-03-11: Zafgen Shares Resume Trade, Down 24.4%

Financial news for ZFGN dated on 2019-03-11: Zafgen Reports Chief Medical Officer Dennis Kim Resigned; Replacement Is Not Mentioned

Financial news for ZFGN dated on 2019-03-11: Zafgen Inc Common Stock Shares To Resume Trade At 4:35 p.m. EDT

Financial news for ZFGN dated on 2019-03-11: Zafgen Q4 EPS \$(0.39) Beats \$(0.44) Estimate

Financial news for ZFGN dated on 2019-03-11: Zafgen Suspends IND Filing Plans For Zgn-1258 Based On Nonclinical Finding In Long-Term Toxicology Studies

Financial news for ZFGN dated on 2019-03-11: Zafgen Shares Halted News Pending

Financial news for ZFGN dated on 2019-03-11: Earnings Scheduled For March 11, 2019

Financial news for ZFGN dated on 2019-03-10: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs

Financial news for ZFGN dated on 2019-02-08: 72 Biggest Movers From Yesterday

Financial news for ZFGN dated on 2019-02-07: Zafgen shares are trading higher after Leerink Swann upgraded the company's stock from Market Perform to Outperform.

Financial news for ZFGN dated on 2019-02-07: 54 Stocks Moving In Thursday's Mid-Day Session

Financial news for ZFGN dated on 2019-02-07: Benzinga's Top Upgrades, Downgrades For February 7, 2019

Financial news for ZFGN dated on 2019-02-07: Leerink Swann Upgrades Zafgen to Outperform

Financial news for ZFGN dated on 2019-01-29: The Daily Biotech Pulse: Big Pharma Earnings, Kiniksa Offering, FDA Decision Day For Aquestive

Financial news for ZFGN dated on 2019-01-28: Stocks Which Set New 52-Week Low Mon., Jan. 28, 2019

Financial news for ZFGN dated on 2019-01-25: The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug

Financial news for ZFGN dated on 2019-01-24: Stocks Which Set New 52-Week Low Yesterday, Jan. 24, 2019

Financial news for ZFGN dated on 2019-01-24: The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial

Financial news for ZFGN dated on 2019-01-17: 22 Stocks Moving In Thursday's Pre-Market Session

Financial news for ZFGN dated on 2019-01-17: Zafgen Announces Results For Second Cohort Of Phase 2 Clinical Trial Of ZGN-1061; Data Showed Statistically Significant Reduction Of A1C, Supported Safety And Tolerability Profile

Financial news for ZFGN dated on 2018-11-27: Zafgen shares are trading lower after after announcing the FDA placed clinical hold on its investigational new drug application for ZGN-1061.

Financial news for ZFGN dated on 2018-11-27: 41 Biggest Movers From Yesterday

Financial news for ZFGN dated on 2018-11-26: Mid-Afternoon Market Update: Dow Up Over 300 Points; JinkoSolar Shares Rise After Q3 Results

Financial news for ZFGN dated on 2018-11-26: 33 Stocks Moving In Monday's Mid-Day Session

Financial news for ZFGN dated on 2018-11-26: Mid-Day Market Update: Crude Oil Up 3%; Zafgen Shares Plummet

Financial news for ZFGN dated on 2018-11-26: Mid-Morning Market Update: Markets Open Higher; Diana Shipping Profit Tops Estimates

Financial news for ZFGN dated on 2018-11-26: UPDATE: Piper Jaffray On Zafgen Clinical Hold: 'We believe the FDA is exercising additional caution following drug-related deaths for discontinued first-gen MetAP2 inhibitor beloranib'

Financial news for ZFGN dated on 2018-11-26: Piper Jaffray Reiterates Overweight Rating, \$18 Price Target On Zafgen With Shares Down 45% Following News Of A Clinical Hold

Financial news for ZFGN dated on 2018-11-26: Zafgen shares are trading down 34.2% premarket after the FDA placed a clinical hold on its investigational new drug application for its first trial of diabetes drug ZGN-1061 due to safety concerns.

Financial news for ZFGN dated on 2018-11-26: Zafgen Shares To Resume Trade At 7:30 a.m. EST

Financial news for ZFGN dated on 2018-11-26: Zafgen Announces the FDA Has Placed a Clinical Hold on the Investigational New Drug Application for the First Trial of ZGN-1061

Financial news for ZFGN dated on 2018-11-26: Zafgen Halted, News Pending

Financial news for ZFGN dated on 2018-11-09: Zafgen Filing Shows REgistration For \$50M Common Stock Offering

Financial news for ZFGN dated on 2018-11-07: Zafgen Q3 EPS \$(0.41) Beats \$(0.48) Estimate

Financial news for ZFGN dated on 2018-11-07: The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie

Financial news for ZFGN dated on 2018-11-04: The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Financial news for ZFGN dated on 2018-09-27: Stocks Which Set New 52-Week High Yesterday, September 26th

Financial news for ZFGN dated on 2018-09-26: Stocks Which Set New 52-Week High Yesterday, September 25th

Financial news for ZFGN dated on 2018-09-26: The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial

Financial news for ZFGN dated on 2018-09-25: Stocks Which Set New 52-Week High Yesterday, September 24th

Financial news for ZFGN dated on 2018-09-21: Stocks Which Set New 52-Week High Yesterday, September 20th

Financial news for ZFGN dated on 2018-08-07: Zafgen Q2 EPS \$(0.57) Beats \$(0.59) Estimate

Financial news for ZFGN dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel

Financial news for ZFGN dated on 2018-08-03: Benzinga's Top Upgrades, Downgrades For August 3, 2018

Financial news for ZFGN dated on 2018-08-03: Wedbush Initiates Coverage On Zafgen with Outperform Rating, Announces \$14 Price Target

Financial news for ZFGN dated on 2018-08-03: The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings

Financial news for ZFGN dated on 2018-08-02: Zafgen Reports Pres, Chief Scientific Officer Thomas Hughes Resigned; Search For Successor Underway

Financial news for ZFGN dated on 2018-07-23: Stocks Which Set New 52-Week Highs Friday

Financial news for ZFGN dated on 2018-07-05: Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index

Financial news for ZFGN dated on 2018-07-05: 45 Biggest Movers From Tuesday

Financial news for ZFGN dated on 2018-07-03: 34 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ZFGN dated on 2018-07-03: Benzinga's Top Upgrades, Downgrades For July 3, 2018

Financial news for ZFGN dated on 2018-07-03: PiperJaffray Initiates Coverage On Zafgen with Overweight Rating, Announces \$18 Price Target

Financial news for ZFGN dated on 2018-06-29: 48 Biggest Movers From Yesterday

Financial news for ZFGN dated on 2018-06-28: Benzinga's Daily Biotech Pulse: Eli

Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut

Financial news for ZFGN dated on 2018-06-28: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for ZFGN dated on 2018-06-28: Zafgen Prices 8M Share Offering at \$.750/Share

Financial news for ZFGN dated on 2018-06-28: Zafgen Prices 8M Share Offering At \$.750/Share

Financial news for ZFGN dated on 2018-06-27: Hearing Zafgen To Offer Shares Of Common Stock In \$7.50-\$7.75/Share Range

Financial news for ZFGN dated on 2018-06-27: Zafgen Reports Offering Of Common Stock, No Size Disclosed

Financial news for ZFGN dated on 2018-06-26: 44 Biggest Movers From Yesterday

Financial news for ZFGN dated on 2018-06-25: Mid-Afternoon Market Update: NASDAQ Down Over 2.5%; Xerium Technologies Shares Spike Higher

Financial news for ZFGN dated on 2018-06-25: Zafgen Shares Up 22.9% After Co. On Saturday Announced Positive Results From Phase 2 Proof-Of-Concept Trial Of ZGN-1061 In Patients With Difficult-To-Control Type 2 Diabetes

Financial news for ZFGN dated on 2018-06-25: 36 Stocks Moving In Monday's Mid-Day Session

Financial news for ZFGN dated on 2018-06-23: Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes at #ADA2018

Financial news for ZFGN dated on 2018-06-17: The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

Financial news for ZFGN dated on 2018-05-08: Zafgen Q1 EPS \$(0.58) Misses \$(0.52) Estimate

Financial news for ZFGN dated on 2018-04-17: 38 Biggest Movers From Yesterday

Financial news for ZFGN dated on 2018-04-16: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for ZFGN dated on 2018-03-07: 31 Stocks Moving In Wednesday's Mid-Day Session

Financial news for ZFGN dated on 2018-03-07: Zafgen Shares Up 2.1%; Tuesday Co. Reported Q4 EPS \$(0.48) vs \$(0.52) Est., Expects To End 2018 With \$40M+ In Cash and Cash Equivalents

Financial news for ZFGN dated on 2018-02-02: 35 Stocks Moving In Friday's Mid-Day Session

Financial news for ZFGN dated on 2018-02-01: 46 Biggest Movers From Yesterday

Financial news for ZFGN dated on 2018-01-05: UPDATE: Zafgen Says 'Company returning to rare disorders with ZGN-1258; Prader-Willi syndrome expected as first indication'

Financial news for ZFGN dated on 2018-01-05: Zafgen Reports 'ZGN-1061 Phase 2 trial fully enrolled with type 2 diabetes patients; topline data expected mid-year'

Financial news for ZFGN dated on 2017-11-07: Zafgen Reports Q3 EPS \$(0.46) vs \$(0.58) Est.

Financial news for ZFGN dated on 2017-10-10: Zafgen Names Jeffrey Hatfield CEO; Thomas Hughes Will Continue As Pres, Named Chief Scientific Officer

Financial news for ZFGN dated on 2017-09-12: Zafgen Initiates Phase 2 Trial For ZGN-1061

Financial news for ZFGN dated on 2017-08-09: S-3 From Zafgen Shows Registration For \$150M Mixed Securities Shelf Offering

Financial news for ZFGN dated on 2017-08-08: Zafgen Reports Q2 EPS \$(0.49) vs \$(0.52) Est.

Financial news for ZFGN dated on 2017-06-11: Zafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at #2017ADA

Financial news for ZFGN dated on 2017-05-09: Zafgen Reports Q1 EPS \$(0.48) vs \$(0.43) In Prior Year Period

Financial news for ZFGN dated on 2017-05-05: 20 Biggest Mid-Day Gainers For Friday

Financial news for ZFGN dated on 2017-05-05: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for ZFGN dated on 2017-05-04: Zafgen Shares Resumed, Stock Now Up 12.5%

Financial news for ZFGN dated on 2017-05-04: Zafgen Shares to Resume Trade at 4:35 p.m. EDT

Financial news for ZFGN dated on 2017-05-04: Zafgen Issues Phase 1 Data for ZGN-1061: Showed Rapid Drug Absorption, Clearance In Line with Pre-Specified Criteria, was Well Tolerated, Safe, No Evidence of Prothrombotic Effects

Financial news for ZFGN dated on 2017-05-04: Zafgen Shares Halted News Pending

Financial news for ZFGN dated on 2017-03-09: Zafgen Reports Q4 EPS \$(0.38) vs. \$(0.50) Est.

Financial news for ZFGN dated on 2017-01-09: 15 Stocks Moving In Monday's Pre-Market Session

Financial news for ZFGN dated on 2017-01-06: 15 Biggest Mid-Day Gainers For Friday

Financial news for ZFGN dated on 2017-01-06: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for ZFGN dated on 2017-01-06: JMP Securities Upgrades Zafgen to Market Outperform

Financial news for ZFGN dated on 2016-12-08: 10 Stocks That Rallied Four Days, Then Sold Off Yesterday

Financial news for ZFGN dated on 2016-11-09: Zafgen Reports Q3 EPS \$(0.54) vs. Est \$(0.61)

Financial news for ZFGN dated on 2016-11-07: 10 Stocks That Plummeted The Past Three Days On Increasing Volume

Financial news for ZFGN dated on 2016-09-20: Zafgen Begins Multiple Ascending Dose Cohorts in Phase 1 Clinical Trial of ZGN-1061

Financial news for ZFGN dated on 2016-09-06: Zafgen Spikes to High of \$3.13 on Volume

Financial news for ZFGN dated on 2016-08-31: CEO Hughes Buys 10,000 Shares of Zafgen @\$3.00/Share -Form 4

Financial news for ZFGN dated on 2016-08-04: Zafgen Reports Q2 EPS \$(0.55) vs. Est. \$(0.66)

Financial news for ZFGN dated on 2016-07-26: CFO Allen Buys 16,000 Shares of Zafgen @\$3.12/Share -Form 4

Financial news for ZFGN dated on 2016-07-21: Option Alert: ZFGN Jan17 2.5 Puts Sweep: 500 @ ASK \$0.40: 1548 traded vs 148 OI: Earnings 8/9 \$2.99 Ref

Financial news for ZFGN dated on 2016-07-20: Mid-Afternoon Market Update: NASDAQ Up Over 1%; Cintas Shares Surge On Upbeat Earnings

Financial news for ZFGN dated on 2016-07-20: 10 Biggest Mid-Day Losers For Wednesday

Financial news for ZFGN dated on 2016-07-20: Mid-Day Market Update: Microsoft Gains Following Earnings Beat; Zafgen Shares Slide

Financial news for ZFGN dated on 2016-07-20: Stocks Hitting 52-Week Lows

Financial news for ZFGN dated on 2016-07-20: Mid-Morning Market Update: Markets Open Higher; Morgan Stanley Beats Q2 Estimates

Financial news for ZFGN dated on 2016-07-20: FBR Capital Downgrades Zafgen to Market Perform

Financial news for ZFGN dated on 2016-07-20: 15 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ZFGN dated on 2016-07-20: Cowen & Company Downgrades Zafgen to Market Perform

Financial news for ZFGN dated on 2016-07-20: Zafgen -45.33% Premarket @\$3.69; Co Announced Tuesday, Suspension Development of Obesity Drug Beloranib

Financial news for ZFGN dated on 2016-07-19: After-Hours Losers: ZFGN Down 41.5%, EXPO 9.7%, IBKR 2.8%, DFS 2.6%, SRPT 2%, UAL 0.5%

Financial news for ZFGN dated on 2016-07-19: Zafgen Suspends Development Of Beloranib, Implementing Strategic Restructuring To Reduce Workforce By 34%; Will Result In Charge Of \$4.8M

Financial news for ZFGN dated on 2016-06-12: Zafgen Announces New Data from the Phase 2b Clinical Trial Evaluating Beloranib in Severe Obesity Complicated by Type 2 Diabetes at the American Diabetes Association's 76th Scientific Sessions

Financial news for ZFGN dated on 2016-06-02: Zafgen Shares Pare Gains, Off Session High of \$7.73 by ~\$0.40; Stock Still Up ~4% for Session

Financial news for ZFGN dated on 2016-06-02: Zafgen Shares Spike ~\$0.30 Over Last Few Mins, Now Up 4.5% for Session

Financial news for ZFGN dated on 2016-05-10: Zafgen Reports Q1 EPS \$(0.65) vs. Est. \$(0.74)

Financial news for ZFGN dated on 2016-04-11: Zafgen Management Really Believes It Will Have Clinical Hold Removed; Decision Could Come In 4-6 Months, Analyst Says

Financial news for ZFGN dated on 2016-04-04: Mid-Morning Market Update: Markets Mostly Flat; Alaska Air To Acquire Virgin America For \$57/Share

Financial news for ZFGN dated on 2016-04-04: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for ZFGN dated on 2016-04-04: Zafgen Shares Surge On Positive Phase 3 Trial

Financial news for ZFGN dated on 2016-04-03: Zafgen Announces Beloranib was Associated with Improvement in Total Cholesterol, LDL Cholesterol, Other Markers of Cardiometabolic Risk

Financial news for ZFGN dated on 2016-03-10: Canaccord Genuity Downgrades Zafgen to Hold

Financial news for ZFGN dated on 2016-03-09: Zafgen Reports Q4 EPS \$(0.85) vs. Est. \$(0.80)

Financial news for ZFGN dated on 2016-02-19: Thromboembolic Risks Linger For Zafgen's Beloranib, Says SunTrust

Financial news for ZFGN dated on 2016-02-18: Here's Why Zafgen Gained 20% Thursday Morning

Financial news for ZFGN dated on 2016-02-18: 10 Stocks Moving In Thursday's Pre-Market Session

Financial news for ZFGN dated on 2016-02-18: Zafgen +19.5% Premarket @\$8.90; Co.'s Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Met Primary Efficacy Endpoint

Financial news for ZFGN dated on 2016-02-18: UPDATE: Zafgen Says Beloranib Showed Statistically, Clinically Significant Improvements in Body Weight, Glycemic Control Over Six Months of Random Treatment

Financial news for ZFGN dated on 2016-02-18: Zafgen Reports Co.'s Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Hit Primary Efficacy Endpoint

Financial news for ZFGN dated on 2016-02-16: Vetr Top Raters Downgrade Zafgen To 1.5-Star Stock

Financial news for ZFGN dated on 2016-01-25: Mid-Day Market Update: Crude Oil Falls 5%; Tyco Shares Surge Following Johnson Controls Merger Agreement

Financial news for ZFGN dated on 2016-01-25: Mid-Morning Market Update: Markets Open Lower; McDonald's Beats Q4 Estimates

Financial news for ZFGN dated on 2016-01-25: Kerrisdale Short Zafgen, Says Beloranib Has 'No Reasonable Chance' Of FDA Approval And Recent Bullishness Is 'Misplaced'

Financial news for ZFGN dated on 2016-01-25: UPDATE: Kerrisdale Believes Zafgen Stock Worth Only \$3/Share

Financial news for ZFGN dated on 2016-01-25: UPDATE: Kerrisdale On Zafgen Short: Recent Excitement About Beloranib Efficacy Is 'Misplaced,' Says Drug Leads To Weight Loss OF 4-5% But Increases Risk Of Death 4X

Financial news for ZFGN dated on 2016-01-25: Zafgen Shares Plummet On Open, Kerrisdale Capital Releases Negative Report; Trading At \$7.56/Share

Financial news for ZFGN dated on 2016-01-25: Kerrisdale Capital Short Zafgen With \$3 Price Target, Says Obesity Drug Has 'No Reasonable Chance' Of FDA Approval

Financial news for ZFGN dated on 2016-01-21: Zafgen Doubles: What Do The Experts Think?

Financial news for ZFGN dated on 2016-01-21: Benzinga's Volume Movers

Financial news for ZFGN dated on 2016-01-21: Benzinga's Top Upgrades

Financial news for ZFGN dated on 2016-01-21: 10 Stocks Moving In Thursday's Pre-Market Session

Financial news for ZFGN dated on 2016-01-21: Zafgen +20.62% Premarket @\$20.11 Following Upgrades at RBC, FBR

Financial news for ZFGN dated on 2016-01-21: RBC Capital Upgrades Zafgen to Outperform

Financial news for ZFGN dated on 2016-01-21: FBR Capital Upgrades Zafgen to Outperform

Financial news for ZFGN dated on 2016-01-21: Zafgen +5.6% Premarket @\$10.61; FBR Upgrades to Outperform With \$20 PT

Financial news for ZFGN dated on 2016-01-20: Mid-Afternoon Market Update: Dow Falls Over 400 Points; Advanced Micro Devices Shares Drop After Disappointing Guidance

Financial news for ZFGN dated on 2016-01-20: Zafgen Up 77% After Positive Results For Obesity Drug

Financial news for ZFGN dated on 2016-01-20: Mid-Morning Market Update: Markets Open Lower; Goldman Sachs Q4 Profit Drops

Financial news for ZFGN dated on 2016-01-20: Why Zafgen Is Trading Higher By 40%

Financial news for ZFGN dated on 2016-01-20: 10 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ZFGN dated on 2016-01-20: UPDATE: Zafgen +80% Premarket @\$10.10; Co Announces Phase 3 Obesity Drug Trial Achieves Co-Primary Efficacy Endpoint

Financial news for ZFGN dated on 2016-01-20: Zafgen +38% Premarket @\$7.75; Co Announces Phase 3 Obesity Drug Trial Achieves Co-Primary Efficacy Endpoint

Financial news for ZFGN dated on 2016-01-20: Zafgen Announces Phase 3 Trial Achieves Co-Primary Efficacy Endpoint

Financial news for ZFGN dated on 2015-12-14: James E. Flynn Reports 4.94% Stake In Zafgen Inc Zfgn.O As Of December 3, 2015 -

Financial news for ZFGN dated on 2015-12-03: Morning Market Losers

Financial news for ZFGN dated on 2015-12-03: Benzinga's Top Downgrades

Financial news for ZFGN dated on 2015-12-03: Benzinga's Top #PreMarket Losers

Financial news for ZFGN dated on 2015-12-03: Early Global News: American Express Expanding In Russia, Baidu To Merge Its Music Business, China Taking Big Steps To Open Market

Financial news for ZFGN dated on 2015-12-03: SunTrust Robinson Humphrey Downgrades Zafgen to Neutral, Lowers PT to \$7.00

Financial news for ZFGN dated on 2015-12-02: Mid-Afternoon Market Update: Dow Slides 150 Points; G-III Apparel Shares Rise On Earnings Beat

Financial news for ZFGN dated on 2015-12-02: Mid-Day Market Update: Crude Oil Drops Over 2.5%; On Deck Capital Shares Surge Following Partnership With JPMorgan

Financial news for ZFGN dated on 2015-12-02: Stocks Hitting 52-Week Lows

Financial news for ZFGN dated on 2015-12-02: Mid-Morning Market Update: Markets Edge Higher; SAIC Earnings Top Expectations

Financial news for ZFGN dated on 2015-12-02: Morning Market Losers

Financial news for ZFGN dated on 2015-12-02: Death Of Another Patient Causes Zafgen's Shares To Plunge

Financial news for ZFGN dated on 2015-12-02: Benzinga's Top #PreMarket Losers

Financial news for ZFGN dated on 2015-12-02: Zafgen -50% Premarket; Co Reported Patient Death in Clinical Update on Beloranib

Financial news for ZFGN dated on 2015-12-02: Zafgen Offers Clinical Update on Beloranib: Co. Learned Patient Who Received Candidate as Part of OLE Portion Has Died

Financial news for ZFGN dated on 2015-11-30: Zafgen Sells Off to Low on Volume

Financial news for ZFGN dated on 2015-11-10: Zafgen Reports Q3 EPS \$(0.73) vs. Est. \$(0.79)

Financial news for ZFGN dated on 2015-10-22: Morning Market Gainers

Financial news for ZFGN dated on 2015-10-22: Benzinga's Top #PreMarket Gainers

Financial news for ZFGN dated on 2015-10-22: Zafgen Says Cause Of Death Of Patient Has Been Determined To Be Respiratory Failure Due To Pulmonary Embolism; Not Known If The Death Of The Patient Was Related To Treatment With Beloranib

Financial news for ZFGN dated on 2015-10-22: Zafgen Expects ZAF-311 to Remain Pivotal Clinical Trial; Says Expects To Report Top-Line Results From ZAF-311, ZAF-203 Clinical Trials In Q1 Of 2016

Financial news for ZFGN dated on 2015-10-22: Zafgen Gives Update on Beloranib

Financial news for ZFGN dated on 2015-10-19: Zafgen Controversy Means Stock Is Worth \$25 Now, Notes SunTrust

Financial news for ZFGN dated on 2015-10-19: Benzinga's Volume Movers

Financial news for ZFGN dated on 2015-10-19: Morning Market Gainers

Financial news for ZFGN dated on 2015-10-19: Benzinga's Top #PreMarket Gainers

Financial news for ZFGN dated on 2015-10-19: Zafgen +6% Premarket; Suntrust Maintained Buy Rating, Lowering PT to \$25 from \$47

Financial news for ZFGN dated on 2015-10-16: Mid-Afternoon Market Update: Crude Oil Rises 2%; Zafgen Shares Dip On Beloranib Partial Clinical Hold

Financial news for ZFGN dated on 2015-10-16: Mid-Day Market Update: Youku Tudou Jumps Following Announcement of Proposal from Alibaba; Quanta Services Shares Slide

Financial news for ZFGN dated on 2015-10-16: Mid-Morning Market Update: Markets Edge Higher; General Electric Profit Tops Expectations

Financial news for ZFGN dated on 2015-10-16: Morning Market Losers

Financial news for ZFGN dated on 2015-10-16: Benzinga's Top #PreMarket Losers

Financial news for ZFGN dated on 2015-10-16: Zafgen Falls 25% Premarket on Beloranib Partial Clinical Hold

Financial news for ZFGN dated on 2015-10-16: UPDATE: Zafgen CEO Says 'Patient safety is our top priority, and we will work closely with the FDA to implement these measures to support the further development of beloranib'

Financial news for ZFGN dated on 2015-10-16: Zafgen Reports Partial Clinical Hold Related to Beloranib Trials

Financial news for ZFGN dated on 2015-10-15: Benzinga's Volume Movers

Financial news for ZFGN dated on 2015-10-14: RBC Spoke With Zafgen Management After

The Beloranib Patient Death; Here Are The Takeaways

Financial news for ZFGN dated on 2015-10-14: Zafgen Shares Spiking To HOD, Up ~30% To \$20.67

Financial news for ZFGN dated on 2015-10-14: Hearing Zafgen Defended At RBC Capital, Chatter RBC Saying Worst Case Scenario Of A Clinical Hold Is Avoided

Financial news for ZFGN dated on 2015-10-14: Zafgen Now +12% as Shares Reverse Course After Hitting Low of \$10.90 on Statement Regarding Patient Death

Financial news for ZFGN dated on 2015-10-14: Shares of Zafgen Resume Following Breaker, Now Down ~20%

Financial news for ZFGN dated on 2015-10-14: UPDATE: Zafgen Shares Halted Down ~11%

Financial news for ZFGN dated on 2015-10-14: Zafgen Shares Halted on Circuit Breaker Following Resumption

Financial news for ZFGN dated on 2015-10-14: Zafgen Trading Down \$14/Share On Phase 3 Patient Death

Financial news for ZFGN dated on 2015-10-14: Reminder Zafgen Shares To Resume Trading At 12:30pm EDT

Financial news for ZFGN dated on 2015-10-14: Zafgen To Resume Trade At 12:30pm ET

Financial news for ZFGN dated on 2015-10-14: UPDATE: Zafgen Says Cause Of Death Of Patient In Phase 3 bestPWS Study of Beloranib Remains Unknown At This Time

Financial news for ZFGN dated on 2015-10-14: UPDATE: Zafgen Says Patient Death Occurred In Company Phase 3 best PWS Study

Financial news for ZFGN dated on 2015-10-14: Zafgen Issues Statement

Financial news for ZFGN dated on 2015-10-14: Zafgen Trading Halted-News Pending

Financial news for ZFGN dated on 2015-10-14: Shares of Zafgen Bounce Off Session Lows Following Earlier Mid-Day Note from SunTrust Defending Stock Amid Massive Decline This Week

Financial news for ZFGN dated on 2015-10-14: Morning Market Gainers

Financial news for ZFGN dated on 2015-10-14: Benzinga's Top #PreMarket Gainers

Financial news for ZFGN dated on 2015-10-14: Zafgen +5% Premarket

Financial news for ZFGN dated on 2015-10-12: Shares of Zafgen Trading Down 32+%; Bloomberg Earlier Reported Co. Cancelled an Event with RBC Amid a Scheduling Conflict

Financial news for ZFGN dated on 2015-10-06: Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

Financial news for ZFGN dated on 2015-09-30: US Stock Futures Jump; ADP Report In Focus

Financial news for ZFGN dated on 2015-09-30: Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Craniopharyngioma

Financial news for ZFGN dated on 2015-09-28: Zafgen Announces Transition of Board of Directors

Financial news for ZFGN dated on 2015-09-09: Zafgen Completes Enrollment of Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes

Financial news for ZFGN dated on 2015-08-11: Zafgen Reports Q2 EPS \$(0.66) vs. Est. \$(0.71)

Financial news for ZFGN dated on 2015-06-17: Zafgen Initiated At Buy, \$47 Target By SunTrust

Financial news for ZFGN dated on 2015-06-17: Benzinga's Top Initiations

Financial news for ZFGN dated on 2015-06-17: Sunturst RObinson Humphrey Initiates Coverage on Zafgen at Buy, Announces \$47.00 PT

Financial news for ZFGN dated on 2015-05-28: Zafgen Completes Enrollment of US Phase 3 Trial of Beloranib in Prader-Willi Syndrome

Financial news for ZFGN dated on 2015-05-12: Zafgen Reports Q1 Loss \$0.53 Vs Exp Loss \$0.65

Financial news for ZFGN dated on 2015-05-08: afgen Presents Positive Safety and Efficacy Data From Phase 2 Trial of Beloranib in Severe Obesity and Proof of Concept Trial in Prader-Willi Syndrome

Financial news for ZFGN dated on 2015-05-07: Zafgen to Make Oral, Poster Presentations at 22nd European Congress on Obesity

Financial news for ZFGN dated on 2015-04-21: Benzinga's Top Initiations

Financial news for ZFGN dated on 2015-04-21: FBR Capital Initiates Zafgen With Outperform

Financial news for ZFGN dated on 2015-04-21: FBR Capital Initiates Coverage on Zafgen at Outperform, Announces \$60.00 PT

Financial news for ZFGN dated on 2015-03-20: Stocks Hitting 52-Week Highs

Financial news for ZFGN dated on 2015-03-19: Zafgen Reports Q4 Loss of \$0.48/Share vs Loss of \$0.84/Share Est.

Financial news for ZFGN dated on 2015-03-19: Earnings Scheduled For March 19, 2015

Financial news for ZFGN dated on 2015-03-07: Zafgen Announces Positive Data from Phase 2 Trial of Beloranib in Hypothalamic Injury Associated Obesity at ENDO 2015

Financial news for ZFGN dated on 2015-01-23: Benzinga's Volume Movers

Financial news for ZFGN dated on 2015-01-23: Zafgen Prices ~3.942M Share Offering @\$35.00/Share

Financial news for ZFGN dated on 2015-01-21: 5 Biotech Secondaries Traders Are Watching

Financial news for ZFGN dated on 2015-01-20: Zafgen Announces 2.8M Share Proposed Public Offering of Common Stock

Financial news for ZFGN dated on 2015-01-13: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3

Financial news for ZFGN dated on 2015-01-12: Zafgen Files for Up to 2.5M Share Offering

Financial news for ZFGN dated on 2015-01-07: Zafgen Announces Positive Results From Phase 2 Study, Primary Endpoint Met

Financial news for ZFGN dated on 2014-12-24: Will Zafgen Continue To Surge Higher?

Financial news for ZFGN dated on 2014-11-11: Zafgen Reports Q3 EPS of \$(0.65) vs \$(0.87) Est

Financial news for ZFGN dated on 2014-10-01: US Stock Futures Edge Lower Ahead Of ADP Report

Financial news for ZFGN dated on 2014-10-01: Zafgen Reports Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome, Trial Will Trigger \$6.7M Milestone Payment Primarily to CKD

Financial news for ZFGN dated on 2014-10-01: Zafgen Initiates Phase 3 Trial of Beloranib in Prader-Willi Syndrome

Financial news for ZFGN dated on 2014-09-25: Zafgen Completes Enrollment Of Phase 2a Trial Of Beloranib In Hypothalamic Injury-Associated Obesity

Financial news for ZFGN dated on 2014-08-13: Zafgen Reports Q2 EPS of \$(2.96) vs \$(3.04) Est

Financial news for ZFGN dated on 2014-08-13: Canaccord Genuity Initiates Coverage on Zafgen at Buy

Financial news for ZFGN dated on 2014-07-29: Benzinga's Top Initiations

Financial news for ZFGN dated on 2014-07-29: JMP Securities Initiates Zafgen At Market Outperform

Financial news for ZFGN dated on 2014-07-29: JMP Securities Initiates Coverage on

Zafgen at Market Outperform, Announces \$31.00 PT

Financial news for ZFGN dated on 2014-07-24: Leerink Swann Initiates Coverage on Zafgen at Outperform, Announces \$35.00 PT

Financial news for ZFGN dated on 2014-07-14: Cowen & Company Initiates Coverage on Zafgen at Outperform, Announces \$45.00 PT

Financial news for ZFGN dated on 2014-07-10: Zafgen Announces Orphan Drug Designation with EU For Beloranib

Financial news for ZFGN dated on 2014-06-26: Zafgen Appoints New Member of Board of Directors; Frank Thomas

Financial news for ZFGN dated on 2014-06-20: IPO Lookout: IPOs Up Double Digits On The Week

Financial news for ZFGN dated on 2014-06-20: Adam Feuerstein Likes Zafgen, Bluebird Bio

Financial news for ZFGN dated on 2014-06-19: Zafgen Opens at \$20/Share, Priced at \$16

Financial news for ZFGN dated on 2014-06-19: Waiting on 5 IPOs This Morning

Financial news for ZFGN dated on 2014-06-18: Zafgen Prices IPO at \$16/Share, 6M Shares Offered

Financial news for ZFGN dated on 2014-06-16: IPO Lookout: 14 IPOs For The Week Of June 16